Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) chronic lymphocytic leukemia (CLL): a matching‐adjusted indirect comparison of 3 randomized phase 3 trials
Ghia, P., Munir, T., Burger, J., Seymour, J. F., Rogers, K., Huang, H., Moreno, C., Neumayr, L., Abbazio, C., Sharman, J.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY
Ghia, P., Allan, J. N., Siddiqi, T., Wierda, W. G., Tam, C. S., Moreno, C., Tedeschi, A., Szafer‐Glusman, E., Zhou, C., Abbazio, C., Dean, J. P., Szoke, A., Barr, P. M.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023
Ghia, P, Munir, T, Burger, J, Seymour, J F, Rogers, K, Huang, H, Moreno, C, Neumayr, L, Abbazio, C, Sharman, J
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article